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Squamous cell carcinomas in psoralen-plus-ultraviolet
A (PUVA) treated patients frequently exhibit p53 tumor
suppressor genes and Ha-ras protooncogenes that are
mutated at dipyrimidine sites and carry the ultraviolet
¢ngerprint (i.e., C-to-T or CC-to-TT transitions). To
further broaden the knowledge of genetic mutations in
PUVA-associated skin cancer, we used DNA sequen-
cing analysis to study the mutational spectrum of the
INK4a-ARF locus in 26 squamous cell carcinomas from
11 long-term PUVA-treated psoriasis patients and clas-
si¢ed the mutations by origin (ultraviolet, ultraviolet
and/or PUVA, or other). Nineteen INK4a-ARF mis-
sense/nonsense mutations were found in exons 1a, 1b,
and 2 in 11 of 26 squamous cell carcinomas (42%) from
seven of 11 patients (64%). Eleven mutations (58%) were
of the ultraviolet type; three (16%) were of the ultravio-
let and/or PUVA type (i.e., C-to-T transitions at dipyr-
imidine sites opposite a 50TpG sequence, a potential
psoralen binding site); and ¢ve (26%) were of other
type. Interestingly, 10 of 11 patients (91%) showed in-
tron polymorphism C500G at the 30 untranslated region
of exon 3. These data indicate that (i) INK4a-ARF mu-
tations frequently occur in PUVA-associated squamous
cell carcinomas; (ii) ultraviolet B radiation is the major
cause of these mutations; and (iii) PUVA itself may play
no direct role in development of most INK4a-ARF
mutations. Key words: carcinogenesis/Ha-ras/mutagenesis/
p53/skin cancer. J Invest Dermatol 120:676 ^682, 2003
P
soriasis patients who undergo long-term treatment
with psoralen plus ultraviolet A (PUVA) and are
exposed to high cumulative dosages of UVA are at
increased risk for skin cancer, particularly squamous
cell carcinoma (SCC) (for review see Stern et al, 1998).
The exact causes and mechanisms of PUVA-associated skin car-
cinogenesis are unclear, however. PUVA is not only a tumor
initiator (Gri⁄n, 1959; Pathak et al, 1959; Kripke et al, 1982;
Ananthaswamy, 1985;Yang et al, 1994; Gunther et al, 1995) and po-
tential tumor promoter by virtue of its in£ammatory properties,
but also an immunosuppressor (Strauss et al, 1980; Kripke et al,
1983). It may thus permit the growth of skin cancers induced by
itself or by other known or suspected carcinogenic agents and
treatments (e.g., therapeutic and/or environmental UV radiation,
ionizing radiation, methotrexate (MTX), topical tar, and/or
arsenic) (Maier et al, 1996).
Using the tools of molecular epidemiology (Perera, 1997), it
may now be possible to determine the exact etiology of di¡erent
types of tumors, including PUVA-associated skin cancers, by
linking mutations at target genes (i.e., tumor suppressor and on-
cogenes) to their causative agents. Indeed, it is already known that
particular carcinogens often cause ‘‘¢ngerprint’’mutations in a tu-
mor suppressor gene and/or oncogene. For instance, a£atoxin B1
induces a speci¢c mutation (G:C to T:A transversion) at codon
249 of the p53 gene in hepatocellular carcinoma (Nataraj et al,
1995). UV-associated murine and human skin cancers exhibit so-
called UV ‘‘¢ngerprint’’ mutations (i.e., C-to-T and CC-to-TT
transitions at dipyrimidine DNA sequences) (Brash et al, 1991;
Campbell et al, 1992; Kress et al, 1992; Rady et al, 1992; Kanjilal
et al, 1993; Moles et al, 1993; Ziegler et al, 1993; 1994; Kubo et al,
1994; Nakazawa et al, 1994; Nelson et al, 1994; Ren et al, 1996).
The application of psoralen and subsequent activation with
UVA light that occurs during PUVA therapy leads to the forma-
tion of DNA photoproducts, which may in turn lead to skin can-
cer formation. In cell culture studies, psoralen photochemically
and preferentially binds to repeated 50TpA sequences, which
makes such sequences primary targets for PUVA mutagenesis.
Monofunctional adducts, which result from C4-cyclo addition
of a psoralen molecule to the 5,6 double bond of pyrimidine bases
(preferentially thymine) in DNA, can react photochemically
with thymine, cytosine, or adenine in complementary DNA
strands, thus resulting in cross-links. One important recent study
demonstrated that PUVA-induced murine skin cancers contained
p53 mutations at DNA cross-linking sites (Nataraj et al, 1996),
with most of the mutations occurring at or near 50TA or 50TAT
sequences. 50TA or 50TAT sequences are potential sites of psora-
lenDNA binding quite di¡erent from those found in UV-in-
duced skin cancers. Repeated AT sequences are particular
hotspots for the photochemical reaction of 8-methoxypsoralen
with DNA, and the reactivity of repeated AT sequences seems to
increase in the following order: ATTAETATATAo
ATAToATATAA (Sage and Moustacchi, 1987; Boyer et al, 1988;
Sage and Bredberg, 1991).
PUVA-associated base substitutions and mutations may also
occur, however, at 50TpG sites (Chiou and Yang, 1995; Gunther
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et al, 1995; Nataraj et al, 1997) and 50TpT sites (Gunther et al, 1995).
Recently, we and others performed molecular epidemiologic se-
quence analyses on the p53 tumor suppressor gene (Nataraj et al,
1997;Wang et al, 1997; Seidl et al, 2001) and Ha-ras protooncogene
(Kreimer-Erlacher et al, 2001) in PUVA-associated nonmelanoma
skin cancers and surprisingly found a high percentage of UV ¢n-
gerprint mutations (i.e., C-to-T and CC-to-TT transitions at di-
pyrimidine sites) in both. This in turn suggested that the damage
caused by UVB exposure may be the most signi¢cant direct fac-
tor, after psoralenDNA photoproducts, in the formation of skin
cancers in PUVA-treated patients. Interestingly, potential PUVA-
associated mutations were more often found at 50TpG sequences
than at 50TpA sequences (Nataraj et al, 1997; Kreimer-Erlacher
et al, 2001). Nevertheless, the lack of p53 and Ha-ras mutations
in up to 46% of these human tumors and the unexpectedly high
percentage of UV ¢ngerprint mutations suggested that other
genes besides p53 and Ha-ras (the most frequently mutated genes
in human cancer) may be involved in PUVA carcinogenesis.
One candidate gene is INK4a-ARF. This locus is localized on
the human chromosome 9p21 and encodes the alternative reading
frame proteins p16INK4a (exons 1a, 2, and 3) and p14ARF (exons
1b, 2, and 3), both of which are involved in the negative control
of cell proliferation and are known to function as tumor suppres-
sors via the retinoblastoma and p53 pathways, respectively (Sou¢r
et al, 1999). Mutations at the INK4a-ARF locus (including UV
¢ngerprint mutations) were ¢rst detected in cutaneous malignant
melanomas (Peris et al, 1999; cited therein) and more recently in
nonmelanoma skin cancers. For instance, Sou¢r et al found
INK4a-ARF mutations in 10% (two of 20) of SCCs from the
general population (Sou¢r et al, 1999) and in 29% (eight of 28)
of nonmelanoma skin cancers (including basal cell carcinomas
and SCCs) from patients with the genetic DNA repair disease
xeroderma pigmentosum (XP) (Sou¢r et al, 2000). They also
found signi¢cant positive associations between the frequency of
p53 mutations on the one hand and p16INK4a and p14ARF muta-
tions on the other. Therefore, in this study, we used tools of mo-
lecular epidemiology [i.e., polymerase chain reaction (PCR)
single-strand conformation polymorphism (SSCP) and DNA se-
quencing analysis] to establish a mutation spectrum for the
INK4a-ARF locus in 26 SCCs from 11 PUVA-treated psoriasis
patients.
MATERIALS ANDMETHODS
Patients and tumors A total of 26 SCCs from 11 PUVA-treated
psoriasis patients were examined for INK4a-ARF mutations. All 11
patients had been previously treated with PUVA and/or had presented for
diagnosis and treatment of skin cancer at the Department of Dermatology
of the University of Graz, Austria. The patients’ demographics, tumor
characteristics, and PUVA treatment data are shown inTable I.
DNA extraction For DNA extraction, para⁄n-embedded specimens
were macrodissected and/or microdissected (i) to eliminate nontumor
tissue from tumor samples and (ii) to obtain normal tissue from each
sample for control PCR-SSCP and DNA sequencing studies. Seven to 10
mM tissue sections on Superfrost Plus slides (Menzel, Braunschweig,
Germany) were depara⁄nized with xylene for 10 min and ethanol for 10
min, air dried, and dampened in deionized water. Tissue was scraped o¡
the slides, suspended in 50^100 ml of a solution containing 0.1 M
TrisHCl (pH 8.0) and 1 mg per ml proteinase K, incubated at 551C
overnight, boiled for 10 min, and ¢nally stored at 201C until analysis.
PCR-SSCP analysis Oligonucleotide primers of INK4a-ARF (exons
1a, 1b, 2, and 3) (Fargnoli et al, 1998) were used in PCRs. Four microliters
of DNA lysate was used as template in a 50 ml solution containing 10 mM
TrisHCl (pH 8.3), 50 mM KCl, 1.5 mMMgCl2 (for exons 1a and 2 parts a
and b) or 2.5 mM MgCl2 (for exons 1b and 3), 100 mM of each dNTP,
























A M III 47 1249 7488 N.A. 16 SCC A1 Lower leg 144
A2 Glans penis 261
B F III 37 1144 7996 UVB, arsenic, tar 25 SCC B1 Lower arm 179
B2 Upper arm 190
B3 Presternal 195
B4 Lower leg 270
B5 Upper leg 280
C M II 54 419 3056 UVB, MTX, tar 27 SCC C1 Lower leg 93
C2 Lower leg 240
D M II 48 445 2778 UVB, tar, X-rays (scalp) 17 SCC D1 Temple 152
D2 Forehead 154
D3 N.A. 239
D4 Lower leg 246
E M II 43 82 222 UVB, MTX, tar 8 SCC E1 Lower leg 51
E2 Lower arm 119
E3 Lower leg 140
F M III 47 813 4352 Tar, arsenic 9 SCC F1 Lower arm 103
F2 Periumbilical 152
G F II 37 622 2732 UVB, tar, X-rays 5 SCC G1 Hand 241
G2 Lower arm 247
H F III 58 1288 6987 UVB 16 SCC H1 Lower leg 181
H2 Lower leg 274
I F III 59 332 1960 Tar 2 SCC I1 Lower leg 146
I2 Lower leg 206
J M II 44 146 728 Tar, X-rays (scalp), arsenic 80 SCC J1 Scalp None
K F III 34 996 5096 UVB, X-rays, tar 4 SCC K1 Upper leg 251
11 6M, 5F 5II, 6III Mean, 46 Mean, 685 Mean, 39457 7UVB, 3 arsenic, 9 tar, 209 SCC 26 Mean, 183
Range 34^59 Range 82^1288 Range 222^7996 4 X-rays, 2 MTX Range 51^280
aF, female; M, male.
bSkin phototype according to Fitzpatrick classi¢cation.
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upstream and downstream primers (64 pM for exon 1a, 120 pM for exon
1b, 30 pM for exon 2 part a, 40 pM for exons 2 part b and 3), 2.5 U of
AmpliTaq Gold Polymerase (Perkin Elmer, Vienna, Austria), and 2.5 ml
dimethylsulfoxide (exons 1a, 1b, and 2). Reaction mixtures were subjected
to 40 cycles of ampli¢cation in a Perkin Elmer Thermocycler Model 6700
(Perkin Elmer, Foster City, CA). Each cycle consisted of denaturation at
941C for 45 s, annealing at 571C (exon 2 part b), 581C (exons 1a and 1b),
or 601C (exons 2 part a and 3) for 30 s, and polymerization at 721C for 30 s.
Before the ¢rst cycle, the PCR tubes were incubated for 12 min at 941C;
after the last cycle, for 7 min at 721C. Tubes without template DNAwere
included in each PCR run to control for potential contamination of
PCRs. For SSCP analysis, PCR products were puri¢ed by gel
electrophoresis on 3% metaphor agarose (FMC Bioproducts, Rockland,
ME) and subsequent gel extraction (Qiagen, Hilden, Germany). Samples
were then applied to a commercially available GeneGel Excel 12.5/24 gel
(Pharmacia Biotech, Uppsala, Sweden) and run for 1 h 45 min at 51C
(exon 2 part a and b), 101C (exons 1b and 3), or 201C (exon 1a). The
running conditions were as follows: voltage, 600 V; current, 25 mA;
power, 15 W. Finally, the gels were stained using a DNA silver staining
kit (Pharmacia Biotech). PCR-SSCP was performed at least twice per
tumor sample.
Direct sequencing In brief, 60 ng of each tumor’s DNAwas ampli¢ed
with 3.2 pM of primer for the di¡erent exons (Fargnoli et al, 1998) (PE
Applied Biosystems,Weiterstadt, Germany). The ampli¢ed products were
then precipitated and analyzed on an ABI Prism 310 system (Perkin
Elmer, Foster City, CA). The PCR-SSCP assay used showed a high
reliability for detecting mutations in exons 2 and 3 of the INK4a-ARF
locus. In most cases (approximately 96%), DNA sequencing con¢rmed
the presence of DNA base changes in samples with shifted (i.e., aberrant)
SSCP bands at exons 2 and 3, but never in samples without aberrant bands
on SSCP gels (data not shown). There was no such good correlation,
however, between SSCP results and the presence or absence of mutations
for DNA sequencing of exons 1a and 1b; thus, in contrast to sequence
analysis for exons 2 and 3 and irrespective of SSCP results, DNA from all
tumor samples was subjected to direct DNA sequencing for exons 1a and
1b. DNA from adjacent normal tumor tissue and human placental DNA
were simultaneously analyzed to rule out PCR-generated mutations.
DNA sequencing was performed twice per tumor sample, and the
presence of a mutation was always con¢rmed by sequencing the opposite
DNA strand. Sequence analysis was done on a Power Macintosh G3
(Apple Computer, Cupertino, CA) using sequence analysis software
(Perkin Elmer).
Statistical analysis For statistical analysis, we used Fisher’s exact test or
the w2 test in the StatViews statistical analysis program version 5.0.1 (SAS
Institute, Cary, NC). pX0.05 was considered to indicate a statistically
signi¢cant di¡erence.
RESULTS
High frequency of UV ¢ngerprint mutations at the INK4a-
ARF locus DNA sequencing analysis revealed 19 INK4a-ARF
missense/nonsense mutations in 11 of 26 SCCs (42%) from seven
of 11 patients (64%) (Table II). Mutations were detected in exons
1a, 1b, and 2 of the INK4a-ARF locus. Three of these 19
mutations (16%) a¡ected the amino acid sequence of both
p16INK4A and p14ARF; 10 mutations (53%) a¡ected only
p16INK4A; and six (32%) a¡ected only p14ARF. Most of the
mutations (17 of 19, 89%) were single-nucleotide substitutions,
except for a two-nucleotide substitution in one case and a 1 bp
deletion in another. Eleven of the 19 missense/nonsense
mutations (58%) were of the UV type; three (16%) were of the
UV and/or PUVA type (i.e., C-to-T transitions at dipyrimidine
sites opposite a 50TpG sequence, a potential psoralen binding
site); and ¢ve (26%) were of other type (including one deletion
at nucleotide position 203 of exon 2) (Fig 1). Two tumors taken
from the lower leg of patient C (C1 and C2) had the same C-to-T
mutation on codon 48 at a site containing multiple (n¼ 3)
pyrimidines. Although tumor C2 was excised more than 12 y
after tumor C1, the fact that the same mutation type was seen in
both cases suggests that tumor C2 may have developed from the
same precursor cell(s) that gave rise to tumor C1 or from tumor
tissue that remained after excision of tumor C1. Importantly,
similar to p53 mutations in PUVA-associated SCC (Nataraj et al,
1997) and basal cell carcinoma (Seidl et al, 2001), all tumors
analyzed in this study contained both wild-type and shifted
SSCP bands. Shifted SSCP bands were often of lower intensity
than wild-type bands, however (data not shown), suggesting that
(i) only one allele was mutated and the other was wild-type and/
or (ii) only a portion of tumor cells harbored mutation(s). No
somatic mutations were found in any sample of normal tumor-
adjacent skin of this study, excluding the presence of not only




















B1 2 gcCag C-T NT UV/PUVA 117 None 132 Gly-Ser
B1 2 acCCgt CC-TT T UV 81 Pro-Leu 95, 96 None, Arg-Cys
B3 2 gcCcg C-T T UV 114 Pro-Leu 128 None
B4 2 ccCgt C-T T UV 114 None 129 Arg-Cys
C1, C2 1a gcCca C-T T UV 38 Pro-Leu None None
C1 1b caCga C-T NT Other None None 24 Val-Met
C1 2 ccCag C-T NT UV/PUVA 110 Trp-Stop 124 None
C1 2 acCcg C-T T UV 79 None 94 Pro-Ser
D2 1a ccCcg C-T NT UV 35 Gly-Arg 32 None
D4 1a taCcc C-T NT UV 25 Val-Ileu None None
E2 2 ggCgc C-T T Other None None 82 Arg-Cys
E2 2 cgCgg Del N.A. N.A. 68 Frameshift 82 Frameshift
F1 2 ccCca C-T NT UV 110 Trp-Stop 125 Gly-Arg
F1 2 cgCgg C-T NT Other 148 Ala-Thr N.A. N.A.
H1 1a gcCag C-T NT UV/PUVA 15 Trp-Stop None None
H1 1a ccCgg C-T NT UV 22 Arg-Gln None None
H1 1b gcCcg C-T T UV None None 17 Pro-Ser
I1 1a ggCgg C-T T Other 34 Ala-Val None None
aNo missense mutations were found in tumors A1, A2, B2, B5, D1, D3, F2, G1, G2, H2, I2, J1.
bThe sequence is shown in 50-30 for the strand (transcribed and nontranscribed) containing the pyrimidines. Mutated bases are written in capital letters. Dipyrimidines
with UV-type mutations (C-T and CC-TT transitions) are underlined once; potential psoralen binding sites (50TpA, 50ApT, 50TpG/50CpA, 50TpT/50ApA sites) with muta-
tions are underlined twice.
cT, transcribed strand; NT, nontranscribed strand.
dCodon designation according to Stott et al (1998).
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PCR-generated mutations but also mutations arising from PCR
across residual carcinogen adducts. In the cases of two patients
(patients E and K), however, all of their tumor and normal
adjacent skin samples showed a C-to-T mutation at codon 148, a
polymorphism that has been previously described (Fargnoli et al,
1998; Aitken et al, 1999; Holland et al, 1999; Goldstein et al, 2000).
This C-to-T base change was also seen in tumor F1 but not in
tumor F2 and in samples taken from normal skin adjacent to
tumors F1 and F2 in the case of patient F, indicating that in
tumor F1 the base change was in fact a somatic mutation.
Interestingly, tumor samples from 10 of 11 patients (91%)
showed the intron polymorphism C500G at the 30 untranslated
region of exon 3, a mutation previously described in malignant
melanomas from patients of Celtic ancestry (Fargnoli et al, 1998;
Aitken et al, 1999).
Mutation frequency and spectrum comparison The
mutation spectrum obtained in this study was compared with a
mutation spectrum derived from pooled data from previous
sequencing studies of the INK4a-ARF locus in SCCs from
normal patients (Kubo et al, 1997; Sou¢r et al, 1999) and XP
patients (Sou¢r et al, 2000). As shown in Fig 2, there was no
signi¢cant di¡erence in percentage of mutation types (UV and/
or PUVA, other) among the di¡erent groups of subjects
[including SCCs of PUVA-treated and non-PUVA-treated non-
XP patients, and SCCs of (presumably non-PUVA-treated) XP
patients] although the number of patients was too small to allow
any de¢nite conclusions to be drawn. Most mutations at the
INK4a-ARF locus in the SCCs from each group of patients were
of the UV type. The total percentage of INK4a-ARF missense or
nonsense UV ¢ngerprint mutations at dipyrimidine sites in SCCs
was 74% (14 of 19) in PUVA-treated patients [or 58% (11 of 19),
when not counting the three C-to-T transitions at 50TpG
sequences], 80% (four of ¢ve) in patients from the general
population, and 78% (seven of nine) in XP patients (Fig 2).
Potential PUVA-type mutations were only seen in SCCs from
XP patients and PUVA-treated patients. As outlined above,
however, in the case of PUVA-associated SCCs, the origin of
these mutations could not be unambiguously traced back to
PUVA or UV due to the DNA sequences at the sites of
mutation (i.e., a dipyrimidine DNA sequence on one DNA
strand and a 50TpG sequence on the opposite strand).
Interestingly, the total percentage of SCCs exhibiting mutations
at the INK4a-ARF locus was 42% (11 of 26) in PUVA-treated
patients, 12% (¢ve of 41) in patients from the general
population, and 33% (six of 18) in XP patients. The di¡erence
between the INK4a-ARF mutation percentage in SCCs from
PUVA-treated patients and that from the general population was
statistically signi¢cant (p¼ 0.0077, Fisher’s exact test).
DISCUSSION
Our DNA sequencing analysis revealed 19 INK4a-ARF missense/
nonsense mutations in 11 of 26 SCCs (42%) from seven of 11
patients (64%) (Table II). Most of these mutations had either
the UV ¢ngerprint (58%) or the UV and/or PUVA ¢ngerprint
(16%). Most (17 of 19, 89%) were single-nucleotide substitutions,
except for a two-nucleotide substitution in one sample and a 1 bp
deletion in another. Interestingly, all UV type mutations were
C-to-T transitions (and one tandem CC-to-TT transition) exclu-
sively found at C-C sequences with the lack of neighboring T.
This is unexpected because for random base mutations one would
expect at least in some cases aTneighboring the C-C sequences at
the mutated sites. The exact reason for the predominance of this
particular mutation type is unknown at present. It does not seem
Figure1. Electropherograms of DNA from two selected tumors.
Top: electropherograms of DNA from (A) tumor E2 and (B) tumor B1.
Bottom: electropherograms of wild-type placental DNA. Arrows in (A) in-
dicate a C-to-T transition and deletion of a cytosine in tumor E2 (i.e., mu-
tations of unspeci¢ed or ‘‘other’’ type) and in (B) a CC-to-TT transition in
tumor B1 (i.e., typical UV ¢ngerprint).
Figure 2. INK4a-ARF mutations detected in SCCs from PUVA-
treated patients versus the general population (Kubo et al, 1997;
Sou¢r et al, 1999) and XP patients (Sou¢r et al, 2000). Note that there
were three C-to-T transitions at dipyrimidine sites, each of which occurred
opposite a 50TpG sequence (a potential psoralen binding site). These muta-
tions are indicated by an asterisk in the column for C-T/CC-TTmutations
and in the column for mutations in 50TpG at dipyrimidine sites. The origin
of these mutations (UV or PUVA) was considered ambiguous, as outlined
in Results.
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to be speci¢c for PUVA-associated skin cancer, however, because
C-to-T transitions at C-C sequences without neighboringT have
been previously found to be more prevalent than other mutation
types in skin cancer from the general population as well, for in-
stance at the p53 gene (Brash et al, 1991; Ziegler et al, 1993). In our
study, no mutation occurred at 50TpA sequences, the most likely
sites for psoralen binding and thus potential markers for a PUVA
e¡ect.
When we compared our results with those of previous studies
on the INK4a-ARF locus in SCCs from normal patients (Kubo
et al, 1997; Sou¢r et al, 1999) and XP patients (Sou¢r et al, 2000),
the mutation spectra were very similar (Fig 2). In those studies,
most of the INK4a-ARF locus mutations (range, 58%80%)
had the UV ¢ngerprint. Potential PUVA-type mutations, how-
ever, were only found in tumors from PUVA-treated patients
and presumably non-PUVA-treated XP patients. Though unu-
sual, the occurrence of PUVA-type mutations in the XP patients
may be explained by exposure to naturally occurring psoralens or
by chance.
In comparing our mutational ¢ndings in the INK4a-ARF
locus with those in p53 and Ha-ras genes (Fig 3), we observed that
potential PUVA-type mutations occur more frequently in the p53
and Ha-ras genes than at the INK4a-ARF locus. This observation
may be explained at least in part by the higher number of psor-
alen binding sites found in the former versus the latter. Indeed, the
percentage of potential psoralen binding sites (i.e., 50ApT/50TpA,
50TpG/50CpA, 50TpT/50ApA sequences) per total DNA length is
32.3% (290/897) at p53 exons 4^9 and 30.4% (173/570) at Ha-ras
exons 1^4, but only 19.4% (128/660) at INK4a-ARF exons 1^3
(INK4a-ARF locus versus Ha-ras or p53, po0.0001, w2 test). In
contrast, the relatively high percentage of UV ¢ngerprint muta-
tions at the INK4a-ARF locus cannot easily be explained by the
number of dipyrimidines at this locus versus the other genes. In-
deed, the percentage of dipyrimidine sites is 20.6% (136/660) at
the INK4a-ARF locus exons 1^3 and 19.8% (113/570) at Ha-ras
exons 1^4, but 29.3% (263/897) at p53 exons 4^9 (INK4a-ARF
locus or Ha-ras versus p53, po0.0001, w2 test).
Three of the 19 INK4a-ARF mutations (16%) a¡ected the cod-
ing region of both p16INK4a and p14ARF, 10 (53%) a¡ected only
that of p16INK4a, and six (32%) a¡ected only that of p14ARF.
Five mutations (26%) were found at mutational sites previously
reported from malignant melanoma. Of those, two [Trp15Stop
(tumor H1) and Pro114Leu (tumor B3)] had been originally seen
in melanoma (FitzGerald et al, 1996; Fargnoli et al, 1998; Holland
et al, 1999). The Trp15Stop mutation (FitzGerald et al, 1996;
Holland et al, 1999) results in a nearly inactive p16INK4a protein
(Holland et al, 1999). In contrast, little is known about the e¡ect of
Pro114Leu on p16INK4a. The remaining three mutations [Pro81-
Leu (tumor B1), deletion at codon 68 (tumor E2), and Gly35Arg
(tumor D2)] represent new variants of mutations at known mu-
tational sites (Walker et al, 1995; Aitken et al, 1999; Hashemi et al,
2000).The Pro81Leu mutation in our study involved base changes
at positions CC242/243TT, whereas the previously reported
Pro81Leu mutation occurred at C242T (Walker et al, 1999). The
deletion of C (base 203) at codon 68 (p16INK4a) in tumor E2
led to a frameshift in both p16INK4a and p14ARF. Here, it is
worth mentioning that Hashemi et al (2000) found a 24 bp dele-
tion at codons 62^69 that resulted in a protein lacking 8 amino
acids in a region that plays an important role in protein function.
The remaining mutations we observed [Pro38Leu (tumors C1
and C2),Trp110Stop (tumor C1),Val25Ileu (tumor D4), Arg22Gln
(tumor H1), and Ala34Val (tumor I1) a¡ecting p16INK4a;
Gly132Ser (tumor B1), Val24Met (tumor C1), Pro94Ser (tumor
C1), Arg82Cys (tumor E2), and Pro17Ser (tumor H1) a¡ecting
p14ARF; and Trp110Stop (tumor F1) a¡ecting both p16INK4a
and p14ARF] have not been reported previously and their e¡ect
on protein function is unknown.
In addition, two of our 11 patients with SCCs (18%) (E and K)
exhibited a previously described polymorphism, i.e., a C-to-T
base change at codon 148 that results in an amino acid change
(Ala148Thr) in the p16INK4a protein (Fargnoli et al, 1998; Aitken
et al, 1999; Holland et al, 1999; Walker et al, 1999; Hashemi et al,
2000; Tsao et al, 2000). This mutation has no functional e¡ect,
however (Walker et al, 1999; Hashemi et al, 2000; Tsao et al,
2000). The prevalence of this polymorphism in our study was
consistent with previous studies, in which it ranged from 11.5%
(15 of 131) (Holland et al, 1999) to 22% (four of 28) (Fargnoli et al,
1998). Interestingly, 10 of 11 patients (91%) exhibited the known
intron polymorphism C500G at the 30 untranslated region of
exon 3 (Fargnoli et al, 1998; Aitken et al, 1999). In an Australian
study, Aitken et al (1999) found that the prevalence of the
C500G polymorphism in patients from families with a history
of melanoma increased linearly from 11.2% in the control group
to 30.4% in the high-risk familial melanoma group. It was sug-
gested that this association probably re£ected the Celtic ancestry
of the patients in the high-risk group. In similar studies, MacKie
et al (1998) found the C500G polymorphism in only one of 16
melanoma families from Australia (6.3%), whereas Fargnoli et al
(1998) found it in seven of 10 melanoma families from Italy and
Austria (70%). In any case, the very high frequency of C500G
polymorphisms in PUVA-treated patients in our study suggests
that it may be a marker of increased risk of PUVA-inducible
SCC.
Taken together, our results and those of previous studies on p53
and Ha-ras in PUVA-associated SCC suggest that mutations in
the INK4a-ARF, p53, and Ha-ras genes occur frequently in these
tumors, which in turn indirectly suggests that there might be
functional cooperation among the proteins resulting from those
mutations. In addition, the fact that all three of these genes show
the UV ¢ngerprint when mutated in PUVA-associated SCCs
suggests that PUVA may somehow promote the mutagenic ef-
fects of UVB (possibly via immunosuppression or tumor promo-
tion) and thus consequently promote carcinogenesis. The likely
reasons for the frequent presence of UV ¢ngerprint mutations
in tumor suppressor genes and/or oncogenes of PUVA-associated
SCCs have been previously discussed in detail (Nataraj et al, 1997;
Kreimer-Erlacher et al, 2001; Seidl et al, 2001). Three of the most
important appear to be (i) a history of therapeutic exposure to
arti¢cial UVB, (ii) habitual exposure to natural sunlight, and
(iii) therapeutic exposure to natural sunlight that is bene¢cial in
Figure 3. Comparison of mutation spectra of human PUVA-associated SCC. Pooled data from the literature on p53 exons 4^9 (Nataraj et al, 1997;
Wang et al, 1997) and Ha-ras exons 1^4 (Kreimer-Erlacher et al, 2001) are compared with data from this study on INK4a-ARF locus exons 1a, 1b, 2, and 3.
Mutation types are de¢ned as inTable II.
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psoriasis (Nataraj et al, 1997). All three of these factors may, alone
or in combination, produce UV ¢ngerprint mutations. Impor-
tantly, most SCCs of this study harboring mutations were located
on the lower legs and arms, representing also the most common
sites of SCC occurrence in those PUVA-treated patients. Psoriatic
lesions particularly on the lower legs are common and often ther-
apy resistant, needing additional therapeutic exposure to treat-
ments such as UVB, PUVA, X-rays, and/or tar, which might be
responsible alone or in combination for the appearance of muta-
tions and tumors at those sites.
In the light of previous cell culture studies (Sage and Bredberg,
1991; Sage et al, 1993; Yang et al, 1994; Chiou and Yang, 1995;
Gunther et al, 1995) and murine studies (Nataraj et al, 1996), it is
di⁄cult to understand the rarity and even absence of mutations
at 50TpA sequences in the INK4a-ARF, p53, and Ha-ras genes in
PUVA-associated SCCs in our study, especially as 50TpA se-
quences are the most likely psoralen binding sites and thus targets
for PUVA carcinogenesis, at least based on cell culture (Sage and
Bredberg, 1991; Sage et al, 1993; Yang et al, 1994; Chiou and Yang,
1995; Gunther et al, 1995) and murine studies (Nataraj et al, 1996). It
has been a consistent ¢nding, in human skin cancer however, that
50TpG sites, but not 50TpA or 50TpT, are the most frequent sites
of potential PUVA type mutations in all genes examined so far.
Potential reasons for the occurrence of sizable portions of muta-
tions at 50TpG sites in humans have been previously discussed
(Nataraj et al, 1997;Wang et al, 1997; Kreimer-Erlacher et al, 2001;
Seidl et al, 2001). Nataraj et al (1997) suggested that the processing
of psoralen adducts in vivo in humans might produce di¡erent
mutation spectra than in rodents or cultured cells. Some have
speculated that, in most in vitro mutagenesis studies, the doses of
PUVA are too high (and thus clinically irrelevant) and result in
mutation spectra that di¡er from those in human cancer (Nataraj
et al, 1997).This hypothesis is supported by the ¢nding that, when
murine ¢broblasts containing supF DNAwere treated with low
doses of PUVA, only 19% of the resulting mutations (eight of
42) occurred at 50TpA sites versus 29% (12 of 42) at 50TpG sites
(Gunther et al, 1995). Interestingly, four of the 19 INK4a-ARFmu-
tations (21%) we observed in this study occurred at CpG sites
and resulted in a C-to-T transition. One possible cause of this
mutation is DNA methylation and deamination (Vogel and
Kopun, 1977; Cooper and Krawczak, 1993; Laird and Jaenisch,
1996) and many studies in eukaryotes (reviewed in Cooper and
Krawczak, 1993) have shown that the CpG dinucleotide is
speci¢cally associated with frequent C-to-T transitions.
In summary, our results demonstrate that (i) mutations at the
INK4a-ARF locus occur frequently in PUVA-associated SCC,
(ii) UVB radiation seems to be the major cause of these muta-
tions, and (iii) PUVA itself may play no direct role in the devel-
opment of most mutations at the INK4a-ARF locus. Taken
together with ¢ndings of previous studies on p53 and Ha-ras,
these results indirectly suggest that PUVA’s primary contribution
to carcinogenesis in PUVA-treated patients may be its potential
for nonmutational e¡ects, such as tumor promotion and/or im-
munosuppression, that in turn promote tumor growth.
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